MacroGenics

MacroGenics is a biopharmaceutical company focused on discovering and developing antibody-based therapeutics designed to modulate the human immune response for the treatment of cancer. The company has a pipeline of product candidates in human clinical testing that have been created primarily using its proprietary technology platforms, which also have applicability across other therapeutic domains, including autoimmune disorders and infectious disease. The company's primary clinical product candidate is margetuximab, a monoclonal antibody that targets human epidermal growth factor receptor 2-expressing tumors, including certain types of breast and gastroesophageal cancers.
  • TickerMGNX
  • ISINUS5560991094
  • ExchangeNASDAQ Stock Market
  • SectorPharmaceuticals & Biotechnology
  • CountryUnited States

Analysts

ValuEngine Rating and Forecast Report for MGNX

ValuEngine Rating and Forecast Report for MGNX

David Nierengarten ...
  • Jeffrey La Rosa

SOPHIA ASCO Abstract Shows PFS Benefit, Trend to OS

ValuEngine Rating and Forecast Report for MGNX

ValuEngine Rating and Forecast Report for MGNX

ValuEngine Rating and Forecast Report for MGNX

ValuEngine Rating and Forecast Report for MGNX

ValuEngine Rating and Forecast Report for MGNX

ValuEngine Rating and Forecast Report for MGNX

ValuEngine Rating and Forecast Report for MGNX

ValuEngine Rating and Forecast Report for MGNX

MACROGENICS INCO. sees a downgrade to Slightly Negative on account of less fundamental stars

The independent financial analyst theScreener just lowered the general evaluation of MACROGENICS INCO. (US), active in the Biotechnology industry. As regards its fundamental valuation, the title now shows 0 out of 4 stars while market behaviour can be considered moderately risky. theScreener believes that the title remains under pressure due to the loss of a star(s) and downgrades its general evaluation to Slightly Negative. As of the analysis date April 12, 2019, the closing price was USD 17.41 and its target price was estimated at USD 10.59.

MarketLine Department

Actinium Pharmaceuticals, Inc. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments

Summary Marketline's Actinium Pharmaceuticals, Inc. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, capital raisings, venture capital investments, ownership and partnership transactions undertaken by Actinium Pharmaceuticals, Inc. since January2007. Marketline's Company Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its c...

Dave Nicoski ...
  • John Betz

Vermilion Booster Shots: Attractive bottom-fishing stocks

For investors looking for bottom-fishing candidates; stocks that are breaking downtrends, exhibiting ascending reaction lows, and showing stabilizing relative strength. For a trial to Vermilion Research visit our website at www.vermilioncap.com or contact our sales team at (952) 922-7500.

ResearchPool Subscriptions

Get the most out of your insights

Get in touch